Missouri Medicine, Jefferson City, Missouri, USA.
North Kansas City Hospital, North Kansas City, Missouri, USA.
Int J Pharm Compd. 2024 Jul-Aug;28(4):286-290.
For the foreseeable future, timolol 0.5% nasal spray prepared by compounding pharmacists will be the only source for a potentially dramatic new paradigm in the treatment of acute migraine.1 It is also likely other medical conditions can be treated with the compounded timolol nasal spray that need extremely rapid therapeutic beta blocker blood levels when IV infusion is not possible or practical. This manuscript will review the research and development of compounded timolol medication over the past dozen years and reference previous articles in IJPC detailing how the pharmaceutical compounded product is prepared.2 A final goal is to engage physicians in a beneficial working relationship with compounding pharmacies to make immediately available to patients a nasal spray formulation of the beta blocker timolol 0.5% in solution. It has recently been demonstrated for the first time to benefit acute migraine treatment.
在可预见的未来,药剂师配制的 0.5%噻吗洛尔鼻喷雾剂将是治疗急性偏头痛这一全新模式的唯一选择。1 此外,当静脉输注不可行或不实际时,其他一些需要迅速达到治疗性β受体阻滞剂血药浓度的疾病也可能通过使用这种复合噻吗洛尔鼻喷雾剂来治疗。本文将回顾过去十年来复合噻吗洛尔药物的研究和开发情况,并参考 IJPC 上的先前文章,详细介绍如何制备这种药物。2 最终目标是让医生与药剂师合作,为患者提供一种现成的 0.5%噻吗洛尔溶液鼻喷雾剂。最近首次证明它对治疗急性偏头痛有效。